Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 + CM313 vs DPd in Relapsed or Refractory Multiple Myeloma
NCT07910903Phase 3Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Dec 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
A Phase 3 trial of gamgertamig, cm313 in multiple myeloma (MM), sponsored by Keymed Biosciences. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
gamgertamigcm313
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07910903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910903.